Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on Thursday, March 4, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 6546156. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
| Last Trade: | US$11.52 |
| Daily Change: | -0.18 -1.54 |
| Daily Volume: | 2,249,391 |
| Market Cap: | US$1.850B |
May 05, 2025 April 14, 2025 April 14, 2025 April 01, 2025 February 26, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
